Biology Reference
In-Depth Information
Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P, Rost KD, Harnest U,
Kroemer B, Albrecht A, Bredenbroker D (2006) Comparison of roflumilast, an oral anti-
inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy
61:72-78
Brunnee T, Engelstatter R, Steinijans VW, Kunkel G (1992) Bronchodilatory effect of inhaled
zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J
5:982-985
Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001) In vivo efficacy in
airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp
Ther 297:280-290
Bureau Y, Handa M, Zhu Y, Laliberte F, Moore CS, Liu S, Huang Z, Macdonald D, Xu DG,
Robertson GS (2006) Neuroanatomical and pharmacological assessment of Fos expres-
sion induced in the rat brain by the phosphodiesterase-4 inhibitor 6-(4-pyridylmethyl)-8-
(3-nitrophenyl) quinoline. Neuropharmacology 51:974-985
Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M,
Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of phospho-
diesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
Nat Biotechnol 28:63-70
Butcher RW, Sutherland EW (1962) Adenosine 3
0
,5
0
-phosphate in biological materials. I. Purifi-
cation and properties of cyclic 3
0
,5
0
-nucleotide phosphodiesterase and use of this enzyme to
characterize adenosine 3
0
,5
0
-phosphate in human urine. J Biol Chem 237:1244-1250
Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM (2007)
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 176:154-161
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ (2009) Roflumilast
in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet
374:685-694
Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim
PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY (2004) Structural
basis for the activity of drugs that inhibit phosphodiesterases. Structure 12:2233-2247
Carpenter DO, Briggs DB, Knox AP, Strominger N (1988) Excitation of area postrema neurones
by transmitters, peptides and cyclic nucleotides. J Neurophysiol 59:358-369
Chan SC, Reifsnyder D, Beavo JA, Hanifin JM (1993) Immunochemical characterization of
the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis.
J Allergy Clin Immunol 91:1179-1188
Cherry JA, Davis RL (1999) Cyclic AMP phosphodiesterases are localized in regions of the mouse
brain associated with reinforcement, movement and affect. J Comp Neurol 407:287-301
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases:
essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
David M, Zech K, Seiberling M, Weimar C, Roflumilast BTD (2004) a novel, oral, selective PDE4
inhibitor, shows high absolute bioavailability. J Allergy Clin Immunol 113:S220-S221, Ref
Type: Abstract
Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A (2007) Inhibition of TGF-beta
induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and
activators of soluble guanylyl cyclase. Eur J Pharmacol 572:12-22
Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang S-K (1997) Differential regulation of
human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic
nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 282:505-512
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF
(2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with
longacting bronchodilators: two randomised clinical trials. Lancet 374:695-703
Fortin M, D'Anjou H, Higgins ME, Gougeon J, Aube P, Moktefi K, Mouissi S, Seguin S, Seguin R,
Renzi PM, Paquet L, Ferrari N (2009) A multi-target antisense approach against PDE4 and
PDE7 reduces smoke-induced lung inflammation in mice. Respir Res 10:39
